Literature DB >> 22569204

PharmGKB summary: phenytoin pathway.

Caroline F Thorn1, Michelle Whirl-Carrillo, J Steven Leeder, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22569204      PMCID： PMC3349446          DOI： 10.1097/FPC.0b013e32834aeedb

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  41 in total

1.  Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore.

Authors:  Gregory M Lipkind; Harry A Fozzard
Journal:  Mol Pharmacol       Date:  2010-07-19       Impact factor: 4.436

Review 2.  Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects.

Authors:  Miriam H Meisler; Janelle E O'Brien; Lisa M Sharkey
Journal:  J Physiol       Date:  2010-03-29       Impact factor: 5.182

3.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Zhi-Sheng Liu; Chien-Hsiun Chen; Mo-Song Hsih; Rosaline Chung-yee Hui; Chia-Yu Chu; Yuan-Tsong Chen
Journal:  Pharmacogenomics       Date:  2010-03       Impact factor: 2.533

4.  In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein.

Authors:  Chunbo Zhang; Patrick Kwan; Zhong Zuo; Larry Baum
Journal:  Life Sci       Date:  2010-04-24       Impact factor: 5.037

5.  Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis.

Authors:  Facundo Garcia Bournissen; Myla E Moretti; David N Juurlink; Gideon Koren; Mugabe Walker; Yaron Finkelstein
Journal:  Epilepsia       Date:  2008-10-24       Impact factor: 5.864

6.  Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations.

Authors:  Elizabeth M Azzato; Renee A Chen; Sholom Wacholder; Stephen J Chanock; Mark A Klebanoff; Neil E Caporaso
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

7.  Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy.

Authors:  Carlos Luna-Tortós; Maren Fedrowitz; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2010-01-18       Impact factor: 5.250

8.  COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.

Authors:  Erwin A van Vliet; Guido Zibell; Anton Pekcec; Juli Schlichtiger; Peter M Edelbroek; Linda Holtman; Eleonora Aronica; Jan A Gorter; Heidrun Potschka
Journal:  Neuropharmacology       Date:  2009-09-26       Impact factor: 5.250

9.  CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Authors:  Amarjit S Chaudhry; Thomas J Urban; Jatinder K Lamba; Angela K Birnbaum; Rory P Remmel; Murali Subramanian; Stephen Strom; Joyce H You; Dalia Kasperaviciute; Claudia B Catarino; Rodney A Radtke; Sanjay M Sisodiya; David B Goldstein; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

10.  Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

Authors:  Chaichon Locharernkul; Jakrin Loplumlert; Chusak Limotai; Wiwat Korkij; Tayard Desudchit; Siraprapa Tongkobpetch; Oratai Kangwanshiratada; Nattiya Hirankarn; Kanya Suphapeetiporn; Vorasuk Shotelersuk
Journal:  Epilepsia       Date:  2008-07-14       Impact factor: 5.864
View more
  17 in total

1.  Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.

Authors:  Supharat Suvichapanich; Jiraphun Jittikoon; Nuanjun Wichukchinda; Wasu Kamchaisatian; Anannit Visudtibhan; Suwat Benjapopitak; Somjai Nakornchai; Wiparat Manuyakorn; Surakameth Mahasirimongkol
Journal:  J Hum Genet       Date:  2015-05-21       Impact factor: 3.172

2.  CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.

Authors:  A Ortega-Vázquez; P Dorado; I Fricke-Galindo; H Jung-Cook; N Monroy-Jaramillo; I E Martínez-Juárez; I Familiar-López; E Peñas-Lledó; A LLerena; M López-López
Journal:  Pharmacogenomics J       Date:  2015-06-30       Impact factor: 3.550

3.  Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.

Authors:  Kittika Yampayon; Chonlaphat Sukasem; Chanin Limwongse; Yotin Chinvarun; Therdpong Tempark; Ticha Rerkpattanapipat; Pornpimol Kijsanayotin
Journal:  Eur J Clin Pharmacol       Date:  2017-04-08       Impact factor: 2.953

4.  Enriched enrollment randomized double-blind placebo-controlled cross-over trial with phenytoin cream in painful chronic idiopathic axonal polyneuropathy (EPHENE): a study protocol.

Authors:  David J Kopsky; Ruben P A van Eijk; Janna K Warendorf; Jan M Keppel Hesselink; Nicolette C Notermans; Alexander F J E Vrancken
Journal:  Trials       Date:  2022-10-22       Impact factor: 2.728

5.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

6.  The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects.

Authors:  Luciana Kase Tanno; Daniel Shikanai Kerr; Bernardo dos Santos; Leda Leme Talib; Célia Yamaguti; Helcio Rodrigues; Wagner Farid Gattaz; Jorge Kalil
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

7.  Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.

Authors:  Tomoko Ota; Yuka Kamada; Mariko Hayashida; Kyoko Iwao-Koizumi; Shigenori Murata; Kenji Kinoshita
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

8.  Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.

Authors:  Natalia Guevara; Cecilia Maldonado; Manuel Uría; Raquel González; Manuel Ibarra; Silvana Alvariza; Antonella Carozzi; Carlos Azambuja; Pietro Fagiolino; Marta Vázquez
Journal:  Pharmaceuticals (Basel)       Date:  2017-08-18

9.  Topical phenytoin for the treatment of neuropathic pain.

Authors:  David J Kopsky; Jan M Keppel Hesselink
Journal:  J Pain Res       Date:  2017-02-27       Impact factor: 3.133

Review 10.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Authors:  Jason H Karnes; Allan E Rettie; Andrew A Somogyi; Rachel Huddart; Alison E Fohner; Christine M Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E Klein; Elizabeth J Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E Caudle; John T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2020-09-06       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.